Abu Dhabi is expanding its ambitions in artificial intelligence-powered healthcare through a new partnership with Isomorphic Labs, a company specialising in AI-driven drug discovery and molecular research.
The agreement, announced during the Abu Dhabi Future Health Summit 2026, brings together the Department of Health – Abu Dhabi (DoH) and Isomorphic Labs to explore how artificial intelligence can improve the early stages of medicine development.
The collaboration will focus on pre-clinical research, using advanced AI technologies and healthcare data to investigate potential drug candidates. Both organisations plan to establish a research roadmap over the next 24 months, supporting Abu Dhabi’s wider efforts to strengthen its position in precision medicine and biotechnology.
Abu Dhabi and Isomorphic Labs Begin 24-Month AI Research Collaboration
The Department of Health – Abu Dhabi and Isomorphic Labs will work together to explore how artificial intelligence can improve drug discovery before potential medicines enter clinical testing. The agreement was signed by Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, and Max Jaderberg, President of Isomorphic Labs.
The collaboration will focus on developing a research roadmap for selected AI-enabled drug discovery projects. Researchers will examine how advanced computational models can help identify biological targets, investigate molecular interactions and assess promising compounds.
Abu Dhabi’s Trusted Research Environment will provide an important foundation for the initiative. This controlled research infrastructure supports the responsible use of sensitive healthcare information while allowing researchers to investigate scientific questions using relevant data.
The partnership does not mean new medicines are ready for clinical trials. Instead, it aims to strengthen the research process that helps scientists decide which potential treatments deserve further investigation.
Isomorphic Labs Brings Advanced AI Technology to Drug Discovery
Isomorphic Labs has developed an AI-powered drug design engine called IsoDDE, which uses advanced computational models to study biological systems and support pharmaceutical research. Its technology focuses on understanding molecular structures and interactions that influence how potential medicines behave.
Discovering new drugs traditionally requires extensive laboratory experiments, repeated testing and significant investment. Researchers must identify suitable biological targets before examining whether particular compounds could interact with them effectively.
Artificial intelligence offers another way to approach that work. By analysing molecular information and predicting possible interactions, AI models can help scientists narrow down research options before committing resources to laboratory testing.
For Abu Dhabi, the partnership provides an opportunity to combine international AI research expertise with its developing healthcare and biotechnology infrastructure. The goal is not to replace scientists but to give them more sophisticated tools for investigating potential treatments.
Genomic Data Could Strengthen Abu Dhabi’s AI Drug Research
Abu Dhabi has spent years developing healthcare data infrastructure and genomic research capabilities, including initiatives such as the Emirati Genome Programme. These investments could become valuable assets as researchers explore how artificial intelligence can support drug discovery.
Genomic information helps scientists understand how genetic variations influence disease risks, biological processes and responses to treatment. When researchers combine these insights with AI models, they may identify new therapeutic targets or investigate treatments for particular patient populations.
This approach also supports the growing field of precision medicine, which aims to develop more personalised strategies for disease prevention, diagnosis and treatment.
One challenge in global pharmaceutical research is that some populations remain underrepresented in genomic studies. Abu Dhabi’s expanding research capabilities could help scientists investigate genetic characteristics relevant to communities in the Middle East.
Any use of sensitive health information will require appropriate safeguards, scientific oversight and responsible data governance. These considerations are especially important as AI systems become more closely connected to healthcare research.
Abu Dhabi Strengthens Its Position in AI-Powered Healthcare
The Isomorphic Labs agreement reflects Abu Dhabi’s broader strategy to develop a healthcare sector built around advanced technology, medical research and international collaboration.
Rather than limiting artificial intelligence to hospital administration or diagnostic tools, the emirate is exploring its applications across pharmaceutical research and biotechnology.
AI-driven drug discovery represents one of the more ambitious areas of this strategy. Pharmaceutical companies and research institutions are increasingly investigating whether machine learning can improve the identification of drug targets, predict molecular behaviour and support the design of new compounds.
These capabilities could help researchers make better decisions during the earliest stages of medicine development. However, laboratory experiments, safety assessments and clinical trials remain essential before any new treatment can reach patients.
Abu Dhabi’s growing combination of healthcare information, genomic research and scientific infrastructure gives it a foundation for participating in this developing field.
International Healthcare Partnerships Support Abu Dhabi’s Research Ambitions
The collaboration with Isomorphic Labs forms part of a wider series of healthcare agreements announced during the Abu Dhabi Future Health Summit 2026.
The Department of Health – Abu Dhabi also announced partnerships involving organisations such as WHOOP, Cleveland Clinic Abu Dhabi and AstraZeneca. These initiatives cover areas including preventive healthcare, clinical research and pharmaceutical development.
Together, the agreements show how Abu Dhabi is building connections between technology companies, healthcare providers and international research organisations.
The Isomorphic Labs partnership concentrates on early-stage drug discovery, while other collaborations address different parts of the healthcare ecosystem. This approach could strengthen the emirate’s ability to support medical innovation from initial scientific research through to clinical investigation.
For international biotechnology companies, Abu Dhabi’s investment in research infrastructure may also create opportunities to explore new partnerships and establish a presence in the region.
AI Drug Discovery Could Shape the Future of Medicine Development
The next 24 months will help determine how the partnership between Abu Dhabi and Isomorphic Labs progresses. Both organisations intend to develop a research roadmap for selected projects, although specific medicines, disease targets and clinical trial schedules have not been publicly confirmed.
The potential benefits of AI-driven drug discovery are significant. Researchers could use advanced models to examine complex biological systems, investigate promising molecular structures and reduce the number of unsuitable compounds that proceed to expensive testing.
Success will depend on whether these predictions translate into reliable experimental results. Drug discovery involves complex biological processes, and even promising candidates can fail during laboratory studies or clinical development.
The agreement nevertheless gives Abu Dhabi an opportunity to participate more directly in the development of AI-enabled pharmaceutical research.
It also highlights a shift in how governments and healthcare organisations view artificial intelligence. Beyond improving existing services, AI is becoming a tool for exploring scientific questions and developing new medical technologies.
Abu Dhabi Builds Momentum in AI-Driven Pharmaceutical Research
Abu Dhabi’s partnership with Isomorphic Labs marks another development in the emirate’s efforts to connect artificial intelligence with healthcare innovation.
By combining advanced drug design technology, genomic research capabilities and international scientific expertise, the collaboration aims to improve how researchers investigate potential medicines.
The immediate priority is establishing a practical research roadmap over the next two years. Whether the initiative eventually contributes to new treatments will depend on the scientific results that follow.
For Abu Dhabi, the agreement strengthens its role in a pharmaceutical research landscape increasingly influenced by artificial intelligence, precision medicine and data-driven discovery.
Sources
- Dubai Eye 103.8 – Abu Dhabi to Advance AI-Driven Drug Discovery Under New Agreement
- Abu Dhabi Media Office – Department of Health Signs Agreements to Advance AI Drug Discover
- GCC Business News – Abu Dhabi DoH Signs Deals to Boost AI Drug Discovery and Clinical Trials
- Department of Health – Abu Dhabi – Strategic Partnership to Accelerate Drug Discover
